Abstract
The aim of this study was to evaluate the GH-releasing activity of a synthetic hexapeptide, GHRP-6, in the Prader-Willi syndrome (PWS). Sixteen PWS patients (7 males and 9 females, aged 12.7–38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9–42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2–14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 μg/kg, iv) or GHRH (1 μg/kg, iv)+PD (60 or 120 mg for children or adults, po). Moreover, in 11 patients with PWS and in the group of SN, the GH response to at least 2 stimulation tests had been previously determined. GH was analyzed either as mean peak values (GHp, mcg/l), or as the area under the curve (AUC, mcg/l/h) and the net incremental area under the curve (nAUC, mcg/l/h). In the group of PWS subjects, GH responses to both GHRP-6 (GHp: 11.4±2.0; AUC: 588±113; nAUC: 483±108) and GHRH+PD (GHp: 7.3±1.8; AUC: 486±122; nAUC: 371±250) were significantly lower than those observed either in OB (GHRP-6: GHp: 25.7±3.2, p<0.003; AUC: 1833±305, p<0.005; nAUC: 1640±263, p<0.0001. GHRH+PD: GHp: 15.1±2.4, p<0.009; AUC: 1249±248, p<0.003; nAUC: 918±230, p<0.006) or in SN patients (GHRP-6: GHp: 39.1±3.1, p<0.0001; AUC: 2792±158, p<0.0001; nAUC: 2705±165, p<0.00005. GHRH+PD: GHp: 27.5±3.7, p<0.0001; AUC: 1873±251, p<0.0001; nAUC: 1692±219, p<0.0005). Unlike control groups, in PWS patients GH levels after GHRP-6 did not differ from those obtained after GHRH+PD. Interestingly, low IGF-I values were present in all PWS subjects. Furthermore, no patient with PWS showed normal GH response to the previously performed GH stimulation tests. As already reported, GH release after GHRP-6 or GHRH+PD was significantly lower in OB than in SN subjects. In conclusion, our data indicate that: 1) GH response to GHRP-6 is clearly impaired in PWS; 2) the blunted GH responses to the provocative stimuli in PWS are not an artifact of obesity; 3) short stature in PWS is caused by a complex dysfunction of the hypothalamo-pituitary structures.
Similar content being viewed by others
References
Bowers C.Y., Sartor A.O., Reynolds G.A., Badger T.M. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 1991, 128: 2027–2035.
Howard A., Feighner S., Cully D., Arena J.P., Liberator P.A., Rosenblum C.I., Hamelin M., Hreniuk D.L., Palyha O.C., Anderson J., Paress P.S., Diaz C., Chou M., Liu K.K., McKee K.K., Pong S.S., Chaung L.Y.P., Elbrecht A., Dashkevicz M., Heavens R., Rigby M., Sirinathsinghji D.J.S., Dean D.C., Melillo D.G., Patchett A.A., Nargund R.P., Griffin P.R., DeMartino J.A., Gupta S.K., Schaeffer J.M., Smith R.G., Van der Ploeg L.H.T. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273: 974–977.
Guillaume V., Magnan E., Cataldi M., Dutour A., Sauze N., Renard M., Razafindraibe H., Conte-Devolx B., Deghenghi R., Lenaerts V., Oliver C. Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep. Endocrinology 1994, 135: 1073–1076.
Bowers C.Y. Editorial: On a peptidomimetic growth hormone-releasing peptide. J. Clin. Endocrinol. Metab. 1994, 79: 940–942.
Korbonits M., Grossman A.B. Growth hormone-releasing peptide and its analogues. Novel stimuli to growth hormone release. Trends Endocrinol. Metab. 1995, 6: 43–49.
Micic D., Popovic V., Kendereski A., Macut D., Casanueva F.F., Dieguez C. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood. Clin. Endocrinol. (Oxf.) 1995, 42: 191–194.
Penalva A., Carballo A., Pombo M., Casanueva F.F., Dieguez C. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6 induced GH secretion in man. J. Clin. Endocrinol. Metab. 1993, 76: 168–171.
Penalva A., Pombo M., Carballo A., Barreiro J., Casanueva F.F., Dieguez C. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6. Clin. Endocrinol. (Oxf.) 1993, 38: 87–91.
Popovic V., Damjanovic S., Micic D., Djurovic M., Dieguez C., Casanueva F.F. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J. Clin. Endocrinol. Metab. 1995, 80: 942–947.
Popovic V., Damjanovic S., Micic D., Petakov M., Dieguez C., Casanueva F.F. Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone, and GH-releasing peptide-6. J. Clin. Endocrinol. Metab. 1994, 79: 456–460.
Ghigo E., Arvat E., Muccioli G., Camanni F. Growth hormone-releasing peptides. Eur. J. Endocrinol. 1997, 136: 445–460.
Pombo M., Leal Cerro A., Barreiro J., Penalva A., Peino R., Mallo F., Dieguez C., Casanueva F.F. Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. J. Pediatr. Endocrinol. Metab. 1996, 9 (Suppl. 3): 333–338.
Scacchi M., Pincelli A.I., Cavagnini F. Growth hormone in obesity. Int. J. Obes. Relat. Metab. Disord. 1999, 23: 260–271.
Argente J., Caballo N., Barrios V., Munoz M.T., Pozo J., Chowen J.A., Hernandez M. Disturbances in the growth hormone-insulin-like growth factor axis in children and adolescents with different eating disorders. Horm. Res. 1997, 48 (Suppl. 4): 16–18.
Cordido F., Penalva A., Peino R., Casanueva F.F., Dieguez C. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6 and pyridostigmine in normal and obese subjects. Metabolism 1995, 44: 745–748.
Burd L., Veselly B., Martsolf J., Kerbeshian J. Prevalence study of Prader-Willi syndrome. Lancet 1985, 2: 828–829.
Donaldson M.D.C., Chu C.E., Cooke A., Wilson A., Greene S.A., Stephenson J.B.P. The Prader-Willi syndrome. Arch. Dis. Child. 1994, 70: 58–63.
Grugni G., Guzzaloni G., Moro D., Bettio D., De Medici C., Morabito F. Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome. Clin. Endocrinol. (Oxf.) 1998, 48: 769–775.
Cappa M., Grossi A., Borrelli P., Ghigo E., Bellone J., Benedetti S., Carta D., Loche S. Growth Hormone (GH) response to combined pyridostigmine and GH-Releasing Hormone administration in patients with Prader-Labhardt-Willi syndrome. Horm. Res. 1993, 39: 51–55.
Holm V.A., Cassidy S.B., Butler M.G., Hanchett J.M., Greenswag L.R., Whitman B.Y., Greenberg F. Prader-Willi syndrome: Consensus diagnostic criteria. Pediatrics 1993, 91: 398–402.
Rolland-Cachera M.F., Sempè M., Guilloud-Bataille M., Patois E., Pequinot-Gugenbuhl F., Fautrad V. Adiposity indices in children. Am. J. Clin. Nutr. 1982, 36: 178–184.
Joint FAO/WHO/UNU: Expert consultation. Energy and protein requirements. WHO Technical Report Series, no. 724, WHO, Geneva, 1985.
Tanner J.M., Whitehouse R.H., Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. Arch. Dis. Child. 1966, 41: 613–635.
Marshall W.A., Tanner J.M. Variation in the pattern of pubertal changes in girls. Arch. Dis. Child. 1969, 44: 291–303.
Marshall W.A., Tanner J.M. Variation in the pattern of pubertal changes in boys. Arch. Dis. Child. 1970, 45: 13–23.
Spiliotis B.E., August G.P., Hung W., Mendelson W., Bercu B.B. Growth hormone neurosecretory dysfunction: a treatable cause of short stature. JAMA 1984, 251: 2223–2230.
Dammacco F., Boghen M.F., Camanni F., Cappa M., Ferrari C., Ghigo E., Giordano G., Loche S., Minuto F., Mucci M., Muller E.E., the Italian Collaborative Group of Neuroendocrinology. Somatotropic function in short stature: evaluation by integrated auxological and hormonal indices in 214 children. J. Clin. Endocrinol. Metab. 1993, 77: 68–72.
Loche S., Pintus S., Cella S.G., Boghen M., Vannelli V., Benso L., Muller E.E., Corda R., Pintor C. The effect of galanin on baseline and GHRH-induced growth hormone secretion in obese children. Clin. Endocrinol. (Oxf.) 1990, 33: 187–192.
Angulo M., Castro-Magana M., Mazur B., Canas J.A., Vitollo P.M., Sarrantonio M. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome. J. Pediatr. Endocrinol. Metab. 1996, 9: 393–400.
Vanderschueren-Lodeweyckx M. The effect of simple obesity on growth and growth hormone. Horm. Res. 1993, 40: 23–30.
Wollmann H.A., Schultz U., Grauer M.L., Ranke M.B. Reference values for height and weight in Prader-Willi syndrome based on 315 patients. Eur. J. Pediatr. 1998, 157: 634–642.
Thacker M.J., Hainline B., St. Dennis-Feezle L., Johnson N.B., Pescovitz O.H. Growth failure in Prader-Willi syndrome is secondary to growth hormone deficiency. Horm. Res. 1998, 49: 216–220.
Costeff H., Holm V.A., Ruvalcaba R., Shaver J. Growth hormone secretion in Prader-Willi syndrome. Acta Paediatr. Scand. 1990, 79: 1059–1062.
Arvat E., Camanni F., Ghigo E. Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Acta Paediatr. 1997, 423 (Suppl.): 92–96.
Loche S., Cambiaso P., Carta D., Setzu S., Imbimbo B.P., Borrelli P., Pintor C., Cappa M. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects. J. Clin. Endocrinol. Metab. 1995, 80: 674–678.
Loche S., Cambiaso P., Merola B., Colao A., Faedda A., Imbimbo B.P., Deghenghi R., Lombardi G., Cappa M. The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency. J. Clin. Endocrinol. Metab. 1995, 80: 2692–2696.
Pombo M., Barreiro J., Penalva A., Peino R., Dieguez C., Casanueva F.F. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection. J. Clin. Endocrinol. Metab. 1995, 80: 3180–3184.
Sieg K.G., Gaffney G.R., Preston D.F., Erikson H.M. SPECT brain imaging of Prader-Willi syndrome using technetium-99m-hexamethylpropyleneamine oxime. Am. J. Med. Genet. 1991, 41: 529.
Butler M.G., Kessler R.M. Positron emission tomography of three adult patients with Prader-Willi syndrome. Dysmorph. Clin. Genet. 1992, 6: 30–31.
Miller L., Angulo M., Price D., Taneja S. MR of the pituitary in patients with Prader-Willi syndrome: size determination and imaging findings. Pediatr. Radiol. 1996, 26: 43–47.
Corrias A., Bellone J., Beccaria L., Bosio L., Trifirò G., Livieri C., Ragusa L., Salvatoni A., Andreo M., Ciampalini P., Tonini G., Crinò A. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of somatotroph responsiveness to various provocative stimuli. J. Endocrinol. Invest. 2000, 23: 84–89.
Hochberg Z., Hertz P., Colin V., Ish-Shalom S., Yeshurun D., Youdim M.B.H., Amit T. The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-1 (IGF-I), and IGF-1 receptors in obesity and anorexia nervosa. Metabolism 1992, 41: 106–112.
Robinson I.C.A.F. Hypothalamic targets for growth hormone secretagogues. Acta Paediatr. 1997, 423 (Suppl.): 88–91.
Casanueva F.F., Micic D., Pombo M., Leal A., Bokser L., Zugaza J.L., Dieguez C. Role of the new growth hormone-releasing secretagogues in the diagnosis of some hypothalamopituitary pathologies. Metabolism 1996, 8 (Suppl. 1): 123–126.
Swaab D.F. Prader-Willi syndrome and the hypothalamus. Acta Paediatr. 1997, 423 (Suppl.): 50–54.
Loche S., Balzano S., Bozzola M., Moretta A., Pintus S., Faedda A., Muntoni A., Carta D., Pintor C. Secretion of growth hormone releasing hormone in obese children. J. Endocrinol. Invest. 1992, 15: 453–457.
Procopio M., Ghigo E., Maccario M., Boffano G.M., Oleandri S.E., Arvat E., Bellone J., Mucci M., Boghen M.F., Camanni F. Effects of arginine, repeated growth hormone (GH)-releasing hormone (GHRH) administration and fasting on the acute GH response to GHRH in obesity. Proceedings International Congress on Growth Hormone and Somatomedins during Lifespan, Milan, Italy, 1992. J. Endocrinol. Invest. 1992, 15 (Suppl. 4): 47 (Abstract).
Low L.C.K., Wang C., Cheung P.T., Ho P., Lam K.S.L., Young R.T.T., Yeung C.Y., Ling N. Long-term pulsatile growth hormone (GH)-releasing hormone therapy in children with GH deficiency. J. Clin. Endocrinol. Metab. 1988, 66: 611–617.
Goth M.I., Lyons C.E., Canny B.J., Thorner M.O. Pituitary adenylate cyclase activating polypeptide growth hormone(GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 1992, 130: 939–944.
Mericq V., Cassorla F., Garcia H., Avila A., Bowers C.I., Merriam G.R. Growth hormone (GH) responses to GH-releasing peptide and to GH-releasing hormone in GH-deficient children. J. Clin. Endocrinol. Metab. 1995, 80: 1681–1684.
Clark R.G., Carlsson L.M.S., Trojnar J., Robinson I.C.A.F. The effects of a growth hormone-releasing peptide and growth hormone-releasing factor in conscious and anaesthetized rats. J. Neuroendocrinol. 1989, 1: 249–255.
Ritzen E.M., Lindgren A.C., Hagenas L., Marcus C., Muller J., Blichfeldt S. Growth hormone treatment of patients with Prader-Willi syndrome. J. Pediatr. Endocrinol. Metab. 1999, 12: 345–349.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grugni, G., Guzzaloni, G. & Morabito, F. Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome. J Endocrinol Invest 24, 340–348 (2001). https://doi.org/10.1007/BF03343871
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343871